On Thursday, the FDA granted full approval to Humacyte, Inc.'s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when ...

Humacyte, a bioengineering company, went public through a SPAC merger in 2015, with a market value of $1.1 billion. The company has received FDA's RMAT designation for three indications, including ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The FDA granted a Priority Review in February 2024 and was assigned a PDUFA date of August 10, 2024. ATEV is a bioengineered human tissue designed to be a universally implantable vascular conduit for ...

Bioengineered organs are no longer just structural substitutes. A review published in Trends in Biotechnology introduces a groundbreaking concept: biohybrid-engineered tissue (BHET) platforms—living ...

A new type of bioengineered blood vessel has shown strong results in treating severe vascular injuries, potentially offering vascular surgeons a better alternative to synthetic grafts when patients' ...

Scientists at the University of Glasgow have successfully used the first bioengineered bone marrow model to carry out vital cancer research, offering new insights into potential therapies for the ...

Humacyte, Inc. has announced that the FDA has granted full approval for SYMVESS, a novel bioengineered human tissue designed for use as a vascular conduit in patients with extremity arterial injuries ...

Scientists from Stanford University have transplanted lab-grown human brain tissue into bioengineered mice.

When children lose their baby teeth, there is an adult set already growing beneath the gums, ready to emerge. But if we lose our permanent teeth, there aren't any more waiting in the wings. Right now, ...